211 related articles for article (PubMed ID: 34956232)
41. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
Front Immunol; 2021; 12():646874. PubMed ID: 33927719
[TBL] [Abstract][Full Text] [Related]
42. TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials.
Choucair K; Morand S; Stanbery L; Edelman G; Dworkin L; Nemunaitis J
Cancer Gene Ther; 2020 Dec; 27(12):841-853. PubMed ID: 32341410
[TBL] [Abstract][Full Text] [Related]
43. Immune cell infiltration-associated signature in colon cancer and its prognostic implications.
Deng D; Luo X; Zhang S; Xu Z
Aging (Albany NY); 2021 Aug; 13(15):19696-19709. PubMed ID: 34349038
[TBL] [Abstract][Full Text] [Related]
44. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
[TBL] [Abstract][Full Text] [Related]
45. Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction.
Wang S; He Z; Wang X; Li H; Liu XS
Elife; 2019 Nov; 8():. PubMed ID: 31767055
[TBL] [Abstract][Full Text] [Related]
46. Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients.
Duffy MJ; Crown J
Clin Chem; 2019 Oct; 65(10):1228-1238. PubMed ID: 31315901
[TBL] [Abstract][Full Text] [Related]
47. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
[TBL] [Abstract][Full Text] [Related]
48. Immune Oncology Biomarkers in Lung Cancer: an Overview.
Travert C; Barlesi F; Greillier L; Tomasini P
Curr Oncol Rep; 2020 Aug; 22(11):107. PubMed ID: 32803433
[TBL] [Abstract][Full Text] [Related]
49. Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review.
Rebuzzi SE; Perrone F; Bersanelli M; Bregni G; Milella M; Buti S
Expert Rev Mol Diagn; 2020 Feb; 20(2):169-185. PubMed ID: 31608727
[No Abstract] [Full Text] [Related]
50. Can CpG methylation serve as surrogate markers for immune infiltration in cancer?
Bacolod MD; Barany F; Fisher PB
Adv Cancer Res; 2019; 143():351-384. PubMed ID: 31202362
[TBL] [Abstract][Full Text] [Related]
51. CD8
Chen X; Xu R; He D; Zhang Y; Chen H; Zhu Y; Cheng Y; Liu R; Zhu R; Gong L; Xiao M; Wang Z; Deng L; Cao K
Oncogene; 2021 Oct; 40(43):6223-6234. PubMed ID: 34552192
[TBL] [Abstract][Full Text] [Related]
52. Atypical patterns of response and progression in the era of immunotherapy combinations.
Ferrara R; Matos I
Future Oncol; 2020 Aug; 16(23):1707-1713. PubMed ID: 32687405
[TBL] [Abstract][Full Text] [Related]
53. [Blood-based Biomarkers in the Immune Checkpoint Inhibitor Treatment in
Non-small Cell Lung Cancer].
Wang P; Tang C; Liang J
Zhongguo Fei Ai Za Zhi; 2021 Jul; 24(7):503-512. PubMed ID: 34187157
[TBL] [Abstract][Full Text] [Related]
54. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
[TBL] [Abstract][Full Text] [Related]
55. The Pan-Cancer Landscape of Crosstalk Between TRP Family and Tumour Microenvironment Relevant to Prognosis and Immunotherapy Response.
Wu G; He M; Yin X; Wang W; Zhou J; Ren K; Chen X; Xue Q
Front Immunol; 2022; 13():837665. PubMed ID: 35493463
[TBL] [Abstract][Full Text] [Related]
56. TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti-CTLA4 treatment.
Li H; Li J; Zhang C; Zhang C; Wang H
Cancer Med; 2020 Oct; 9(19):7151-7160. PubMed ID: 32810393
[TBL] [Abstract][Full Text] [Related]
57. Predictive Biomarkers for Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Current Status and Future Directions.
Bhalla S; Doroshow DB; Hirsch FR
Cancer J; 2020; 26(6):507-516. PubMed ID: 33298722
[TBL] [Abstract][Full Text] [Related]
58. Higher TLR7 Gene Expression Predicts Poor Clinical Outcome in Advanced NSCLC Patients Treated with Immunotherapy.
Baglivo S; Bianconi F; Metro G; Gili A; Tofanetti FR; Bellezza G; Ricciuti B; Mandarano M; Teti V; Siggillino A; Reda MS; Chiari R; Pistola L; Sidoni A; Minotti V; Roila F; Ludovini V
Genes (Basel); 2021 Jun; 12(7):. PubMed ID: 34209514
[TBL] [Abstract][Full Text] [Related]
59. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma.
Fröhlich A; Loick S; Bawden EG; Fietz S; Dietrich J; Diekmann E; Saavedra G; Fröhlich H; Niebel D; Sirokay J; Zarbl R; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
EBioMedicine; 2020 Feb; 52():102647. PubMed ID: 32028068
[TBL] [Abstract][Full Text] [Related]
60. Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies.
Hernandez C; Arasanz H; Chocarro L; Bocanegra A; Zuazo M; Fernandez-Hinojal G; Blanco E; Vera R; Escors D; Kochan G
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]